Age-related efficacy of Shigella O-specific-polysaccharide conjugates in 1 to 4 year-old Israeli children

BACKGROUND: Despite its high worldwide morbidity and mortality, there is yet no licensed vaccine for shigellosis. We reported the safety and immunogenicity of Shigella O-specific polysaccharide-protein conjugates in adults and young children and efficacy of Shigella sonnei conjugate in young adults....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Vaccine
Autors principals: Passwell, Justen H., Ashkenzi, Shai, Banet-Levi, Yonit, Ramon-Saraf, Reut, Farzam, Nahid, Lerner-Geva, Liat, Even-Nir, Hadas, Yerushalmi, Baruch, Chu, Chiayung, Shiloach, Joseph, Robbins, John B., Schneerson, Rachel
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6503522/
https://ncbi.nlm.nih.gov/pubmed/20056180
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2009.12.050
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars